Journal of Biochemistry and Biotechnology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Commentary - Journal of Biochemistry and Biotechnology (2024) Volume 7, Issue 6

AI in Precision Medicine: Tailoring Treatments to Individual Genomes

Ahmed Al-Mahdi*

Center for Bioethics, University of Baghdad, Iraq

*Corresponding Author:
Ahmed Al-Mahdi
Center for Bioethics
University of Baghdad, Iraq
E-mail: ahmed.almahdi@email.com

Received: 04-Dec-2024, Manuscript No. AABB-24-153758; Editor assigned: 05-Dec-2024, Pre QC No. AABB-24-153758 (PQ); Reviewed: 12-Dec-2024, QC No. AABB-24-153758; Revised: 19-Dec-2024, Manuscript No. AABB-24-153758 (R); Published: 26-Dec-2024, DOI:10.35841/aabb-7.6.235

Citation: Al-Mahdi A. AI in Precision Medicine: Tailoring Treatments to Individual Genomes. J Biochem Biotech 2024; 7(6):235.

Visit for more related articles at Journal of Biochemistry and Biotechnology

Introduction

The advent of precision medicine represents a paradigm shift in healthcare, moving away from a one-size-fits-all approach to personalized treatments based on an individual's genetic makeup. Artificial intelligence (AI) is at the heart of this transformation, enabling the analysis of vast amounts of genomic, clinical, and lifestyle data to identify tailored therapies. AI's ability to rapidly process complex datasets, recognize patterns, and make predictions is revolutionizing precision medicine, offering hope for more effective treatments with fewer side effects. This article explores how AI is driving the precision medicine revolution, highlighting its current applications and future potential [1].

Precision medicine seeks to provide customized healthcare solutions by considering an individual’s unique genetic, environmental, and lifestyle factors. Genomic data, in particular, plays a pivotal role in this approach, as genetic variations can influence how patients respond to drugs. AI algorithms, including machine learning (ML) and deep learning (DL), are instrumental in interpreting this data, identifying disease risk factors, and predicting responses to treatments. By leveraging AI, healthcare providers can develop personalized treatment plans, optimizing outcomes for conditions ranging from cancer to cardiovascular disease [2].

The human genome contains approximately 3 billion base pairs of DNA, and deciphering this complex code to identify relevant genetic variants is a monumental task. AI excels in managing such vast datasets, using advanced algorithms to sift through genomic data and identify patterns associated with disease. AI models can recognize genetic mutations or single nucleotide polymorphisms (SNPs) that may predispose an individual to certain conditions or affect their response to drugs. This capability allows researchers and clinicians to make more informed decisions regarding prevention and treatment strategies [3].

Cancer treatment is one area where AI has shown significant promise in precision medicine. By analyzing the genetic mutations in a patient’s tumor, AI can help identify targeted therapies that are more likely to be effective. For example, IBM Watson for Genomics has been used to analyze cancer patients’ genetic data and suggest personalized treatment options. In one case, Watson identified a rare genetic mutation in a cancer patient, leading to the recommendation of a targeted therapy that significantly improved the patient’s condition. This highlights AI’s potential to transform cancer treatment by identifying tailored therapies based on individual genetic profiles [4].

Pharmacogenomics, the study of how genes influence a person's response to drugs, is another key area of precision medicine. AI tools can analyze genomic data to predict how patients will metabolize certain drugs, helping to avoid adverse drug reactions and improving treatment efficacy. For example, the AI platform YouScript uses pharmacogenomic data to identify drug-gene interactions and recommend optimized drug regimens for individual patients. By personalizing drug therapy based on genetic information, AI can reduce the risk of harmful side effects and improve patient outcomes, particularly in managing chronic diseases like diabetes and hypertension [5].

Rare diseases, which affect a small percentage of the population, often go undiagnosed or misdiagnosed due to the lack of available data and clinical knowledge. AI is helping to address this challenge by analyzing genomic data to identify genetic mutations linked to rare diseases. AI-powered platforms such as DeepGestalt, which uses facial recognition technology to identify genetic syndromes based on facial features, are making breakthroughs in diagnosing rare genetic disorders. By integrating genomic and phenotypic data, AI systems can pinpoint the underlying genetic causes of rare diseases, leading to earlier diagnosis and more effective treatments [6].

In addition to identifying personalized treatments, AI is also being used to predict disease risk based on genetic and environmental factors. Polygenic risk scores (PRS), which aggregate the effects of multiple genetic variants, are increasingly being used to assess an individual's predisposition to diseases such as heart disease, diabetes, and Alzheimer's. AI algorithms can analyze genetic data alongside lifestyle factors like diet, exercise, and environmental exposures to generate more accurate risk predictions. This information empowers individuals to take preventive measures or engage in early interventions to reduce their disease risk [7].

While AI offers significant potential in precision medicine, it also raises important ethical and privacy concerns. The use of genomic data, which is highly sensitive, requires stringent measures to protect patient privacy. There are concerns about how genetic information might be used by third parties, such as insurers or employers, leading to potential discrimination. Additionally, the complexity of AI decision-making processes, often described as a "black box," raises questions about transparency and accountability. It is crucial to establish robust ethical guidelines and regulatory frameworks to ensure that AI-driven precision medicine is conducted in a way that protects patient rights and maintains public trust [8].

As AI continues to advance, its role in precision medicine will likely expand. The integration of AI with other emerging technologies, such as CRISPR gene-editing and next-generation sequencing (NGS), will enable even more precise manipulation of genetic data for therapeutic purposes. AI could also play a role in the development of personalized vaccines, such as those designed to target specific cancer mutations. Additionally, AI-driven drug discovery platforms will continue to identify novel compounds tailored to individual genomic profiles, potentially shortening the timeline for developing personalized treatments [9,10].

Conclusion

AI is revolutionizing the field of precision medicine, offering unprecedented opportunities to tailor treatments to individual genomes. From analyzing vast amounts of genomic data to predicting disease risk and identifying targeted therapies, AI has the potential to make healthcare more personalized, effective, and efficient. While challenges related to data privacy, ethical considerations, and regulatory oversight remain, the future of AI in precision medicine looks promising. As AI technology continues to evolve, it will play a central role in transforming how diseases are diagnosed, treated, and prevented, ultimately leading to better patient outcomes and more individualized care.

References

  1. Topol E. Deep medicine: how artificial intelligence can make healthcare human again. 2019.

    2. Indexed at, Google Scholar

  2. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24-9.

    3. Indexed at, Google Scholar, Cross Ref

  3. Kourou K, Exarchos TP, Exarchos KP. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8-17.

    4. Indexed at, Google Scholar, Cross Ref

  4. Krittanawong C, Zhang H, Wang Z. Artificial intelligence in precision cardiovascular medicine. J Am Coll Cardiol. 2017;69(21):2657-64.

    5. Indexed at, Google Scholar, Cross Ref

  5. Brasil S, Pascoal C, Francisco R, et al. Artificial intelligence (AI) in rare diseases: is the future brighter?. Genes. 2019;10(12):978.

    6. Indexed at, Google Scholar, Cross Ref

  6. Dias R, Torkamani A. Artificial intelligence in clinical and genomic diagnostics. Genome Med. 2019;11(1):70.

    7. Indexed at, Google Scholar, Cross Ref

  7. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521(7553):436-44.

    8. Google Scholar

  8. Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463-77.

    9. Google Scholar

  9. Quazi S. Artificial intelligence and machine learning in precision and genomic medicine. Med Oncol. 2022;39(8):120.

    10. Google Scholar

  10. Korngiebel DM, Thummel KE, Burke W. Implementing precision medicine: the ethical challenges. Trends Pharmacol Sci. 2017;38(1):8-14.

    11. Google Scholar

Get the App